Increasing attention has been placed on the utility of SGLT2 inhibitors because, in addition to controlling blood glucose levels, they have been shown to provide significant cardiovascular benefits in T2DM patients (Packer et al., 2021). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.